

THE IMPORTANCE OF INTELLECTUAL PROPERTY IN THE BIOPHARMACEUTICAL RESEARCH ECOSYSTEM

Science is a series of steps. With each step, you get closer to achieving the goal. The process of developing and bringing a new drug to market is a massive undertaking. It requires thousands of individuals and many years before it actually reaches patients. Protection of the inventive research is critical to the innovation ecosystem.

“Good ideas can happen in any aspect of the pharmaceutical industry, be that in the public sector, universities, and the National Institutes of Health. We want to incentivize all these individuals to work together to bring their best ideas to the table and leverage each individual member of the sectors’ strengths to create the greatest number of possibilities for bringing treatments to patients.”


Tonya Combs

vice president and deputy general patent counsel of IP procurement, Lilly

The Elixir Factor: “Protecting Ideas Drives Innovation,” 2020.

THE BAYH-DOLE ACT WITHIN THE BIOPHARMACEUTICAL RESEARCH SYSTEM

The entrepreneurial biopharmaceutical research ecosystem in the United States is fueled by competition and collaboration, ensuring everyone involved is producing the best product, taking risks and sharing information throughout the process. The biopharmaceutical industry’s unique role is to use their expertise to build upon and further advance basic science research into safe and effective treatments for the end users – patients in need.



BAYH-DOLE ACT

Federally supported research is a fundamental part of the U.S.’s world leading, biopharmaceutical ecosystem. The Bayh-Dole Act, passed in 1980, enables universities, non profit research institutions and small businesses to retain title to intellectual property arising from government funded research by patenting their groundbreaking discoveries.

These inventions can then be licensed to private sector partners who further develop them for commercialization and public use. Licensing agreements reward research institutions and help fund additional basic scientific research. By funding and protecting the intellectual property in the drug discovery process, the Bayh-Dole Act incentivizes new ideas in the biopharmaceutical ecosystem.

BENEFITS OF THE BAYH-DOLE ACT



Developed more than 200 new medicines since 1980.



Generated an estimated 4.2 million jobs in the U.S. since 1996.



Produced nearly \$591 billion in U.S. gross domestic product. (1996–2015)




The United States leads the world in biopharmaceutical innovation.

Lori Pressman, et al. AUTM 2017; 3-14

To learn more, tune into Season 2, Episode 7 of the Elixir Factor, “Protecting Ideas Drives Innovation.”

Stream the Elixir Factor everywhere you listen to podcasts! New episodes now available.

ELIXIR FACTOR™



FIND OUT MORE AT LILLY.COM